Steve Stevens turns the clock back to May 1986 to tell us all about the Hamer SS1 he is holding on the cover of GW, and what ...

RKLX, the Defiance Daily Target 2X Long RKLB ETF, seeks daily investment results that correspond to twice (200%) the daily percentage change of Rocket Lab, a company at the forefront of satellite ...

“The connections and memories we’re able to make with ‘Be Legendary’ have been incredible,” said Clijsters. As a child, Clijsters’ historic role models were Stefanie Graf and Monica Seles. “My sister ...

The sign can display different messages, including the CSX logo, "Go Jags" during Jaguars games ... of downtown and another $10 million for the new Museum of Science and History that will be built ...

Telehealth and wellness platform Hims & Hers on Monday offered a revenue outlook for the year ahead that topped Wall Street’s expectations, but shares fell hard in after-hours trading ...

Hims and Hers' stock fell over 19% in after-hours trading on Monday after its CEO said the company would no longer sell compounded versions of mega-hit weight loss drugs. "We will have to start ...

The move: Hims & Hers stock plunged by as much as 27% on Tuesday, hitting an intraday low of $37.29. The stock is down by 49% from its peak of $72.98 last week. The chart: Why: Hims & Hers said it ...

Hims & Hers (HIMS) stock is sinking 20% today after Eli Lilly (LLY) unveiled significantly cheaper versions of its popular weight-loss drugs today. Additionally, the FDA last week hindered the ...

Hims & Hers reported a double beat with Q4 revenue at $481M, a 95% YoY improvement, but faced an 18% stock drop after hours. Despite margin contraction due to new weight loss offerings, adjusted ...

Hims & Hers is stopping its sales of an alternative to blockbuster weight-loss drugs Wegovy and Ozempic. That follows the U.S. Food and Drug Administration's declaration that the shortage of ...